GlassScriptPhysician profile
Rekha Vijayan
NPI 1730406836
$761.15
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $42.45 · 2022: $20.48 · 2023: $417 · 2024: $44.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $462.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $462.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $171.57 | 2023 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $89.83 | 2019-2023 | Nuedexta |
| Teva Pharmaceuticals USA, INC. | $62.07 | 2019-2023 | Austedo Xr |
| Alkermes, INC. | $54.41 | 2019-2023 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $53.18 | 2019 | |
| Neurocrine Biosciences, INC. | $52.62 | 2019-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $52.45 | 2019-2023 | Trintellix |
| Corium, LLC | $42.94 | 2023-2024 | Azstarys |
| Axsome Therapeutics, INC. | $40.48 | 2023-2024 | Auvelity |
| Lundbeck LLC | $31.70 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $23.92 | 2023 | Invega Sustenna, Invega Trinza, Spravato |
| Supernus Pharmaceuticals, INC. | $19.51 | 2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $18.93 | 2019 | |
| Tris Pharma INC | $17.23 | 2019 | |
| Vanda Pharmaceuticals INC. | $16.58 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $13.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rekha Vijayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.